DOSE — Rapid Dose Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- CA$24.76m
- CA$27.35m
- CA$0.72m
- 39
- 12
- 85
- 42
2019 February 28th | 2020 February 29th | R2021 February 28th | 2022 February 28th | 2023 February 28th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.102 | 0.755 | 1.75 | 0.718 |
Cost of Revenue | |||||
Gross Profit | — | 0.037 | 0.7 | 1.34 | 0.372 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 11.5 | 7.72 | 2.53 | 10.3 | 4.53 |
Operating Profit | -11.5 | -7.61 | -1.78 | -8.52 | -3.81 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.4 | -7.96 | -1.81 | -8.49 | -3.81 |
Net Income After Taxes | -11.4 | -7.96 | -1.81 | -8.49 | -3.81 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.4 | -7.96 | -1.81 | -8.49 | -3.81 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.4 | -7.96 | -1.81 | -8.49 | -3.81 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.051 | -0.106 | -0.022 | -0.043 | -0.037 |